TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15927285
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration (28 patients)
Study: 10824633
Drug: Flumazenil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.4 mg)
Study: 8570774
Drug: Physostigmine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.5 mg)
Study: 10216324
Drug: Placebo (physiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiologic saline solution)
Study: 1615141
Drug: Scopolamine hydrobromide,
Normalized name: Scopolamine Hydrobromide, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine hydrobromide, 0.43 mg/70 kg, administered by subcutaneous injection
Study: 3925478
Drug: Scopolamine 1.2
Normalized name: scopolamine 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 1.2 mg
Study: 6425892
Drug: Nicotine 0.5
Normalized name: nicotine 0.583 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 0.5 mg, 1.0 mg, and 1.5 mg
Study: 29847967
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (1 μg/kg)
Study: 23800984
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (5 mg/kg)
Study: 23800984
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine and ketamine
Study: 18833106
Drug: Torin (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torin (generic sertraline)
Study: 29668399
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and Alternative Medicine (CAM)
Study: 23582638
Drug: Recombinant adenovirus
Normalized name: Adenovirus/PNP
DrugBank: Adenovirus/PNP (DB17175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adenovirus HIV1 vaccine
Study: 19142413
Drug: Aripiprazole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (mean dose 9.6 mg/day)
Study: 12970729
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 1% lignocaine in the periprostatic tissue prior to biopsy
Study: 8672415
Drug: Cholecalciferol administration
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol administration
Study: 1596003
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release theophylline (Theodur)
Study: 9313279
Drug: No cream
Normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No cream (control group)
Study: 27184759
Drug: 3000µg/month oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000µg/month oral vitamin D3 by the mother (group A)
Study: 16634838
Drug: Cinnamon extract
Normalized name: Cinnamon Extract
DrugBank: Chinese cinnamon (DB16593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon extract (3 g of cinnamon powder per day)
Study: 12050274
Drug: Risperidone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4 mg/d)
Study: 11328775
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg/day
Study: 9041573
Drug: Ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.1 mg.kg‐1, maximum 4 mg)
Study: 7949641
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) therapy
Study: 26712288
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of povidone-iodine solution
Study: 21788077
Drug: Latanoprost ophthalmic
Normalized name: latanoprost ophthalmic
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost ophthalmic solution 0.005% administered once daily in 1 or both eyes for ≥2 weeks.
Study: 16951643
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg once daily
Study: 16218173
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 400/100 mg twice daily
Study: 22872692
Drug: Leptin replacement
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin replacement therapy
Study: 10078401
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron i.v.
Study: 10078401
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4 mg ondansetron and 8 mg dexamethasone i.v.
Study: 2160758
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/day for 6 days)
Study: 7382535
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (0.25 mg/kg hydralazine)
Study: 24906295
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) therapy
Study: 29276777
Drug: Dentist-provided treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentist-provided treatments (glutaraldehyde/HEMA compounds, oxalates, bonding agents)
Study: 29276777
Drug: Dentists' advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentists' advice and counseling regarding oral habits and diet
Study: 19018143
Drug: Ezetimibe/simvastatin 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/40 mg
Study: 21400791
Drug: Atropine administration
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine administration in traditional subarachnoid anesthesia (SA) protocol
Study: 21400791
Drug: Atropine administration
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine administration in traditional SA protocol
Study: 17591533
Drug: Lisinopril (ACE-inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (ACE-inhibitor group; 36 patients)
Study: 17591533
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (control group; 34 subjects)
Study: 7888983
Drug: Citalopram (C)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (C) 40 mg/day
Study: 2240139
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy with methanol-extracted residue of bacille Calmette-Guerin
Study: 2240139
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy
Study: 805675
Drug: Propranolol 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 320 mg
Study: 20559037
Drug: 7vPnC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7vPnC vaccine with CPG 7909 adjuvant
Study: 20559037
Drug: 7vPnC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7vPnC vaccine with placebo adjuvant
Study: 10673910
Drug: Inulin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (up to 34 g/d)
Study: 1518257
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose MTX (4 x 0.5 g/m2) in standard risk patients.
Study: 19374294
Drug: Tranexamic acid,
Normalized name: Tranexamic Acid, 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranexamic acid, 250 mg four times a day for 5 days
Study: 28606216
Drug: 6.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.2 g/d n-3 PUFA (3.7 g EPA and 2.5 g DHA)
Study: 28606216
Drug: 3.1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.1 g/d n-3 PUFA (1.8 g EPA and 1.3 g DHA)
Study: 28606216
Drug: 6.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.2 g/d n-3 PUFA
Study: 28606216
Drug: 3.1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.1 g/d n-3 PUFA
Study: 21719095
Drug: 14-day full-dose
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day full-dose teplizumab
Study: 21719095
Drug: 14-day low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-day low-dose teplizumab
Study: 21719095
Drug: 6-day full-dose
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-day full-dose teplizumab
Study: 19032601
Drug: L-NMMA (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (0.5 mg kg(‐1) min(‐1))
Study: 20142447
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitors
Study: 15338070
Drug: H1-/H2-histamine antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-/H2-histamine antagonists
Study: 15338070
Drug: Histamine releaser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine releaser compound 48/80
Study: 11836849
Drug: Trimetazidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (40 mg bolus i.v. then 60 mg per day for 48 hours intravenously in glucose infusion)
Study: 9951746
Drug: Anticardiolipin antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibody presence in Group 2 (fertile women)
Study: 8053971
Drug: Chlorpropamide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide 0.5 once daily morning
Study: 24798113
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository
Study: 26242466
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg/day for 3 weeks
Study: 19381108
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment or placebo
Study: 15795533
Drug: Roxifiban (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (1 mg BID for 9 days)
Study: 15795533
Drug: Roxifiban (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (30 nmol/l free acid added to blood from roxifiban-treated subjects)
Study: 11985760
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n=59)
Study: 11985760
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (n=53)
Study: 9793620
Drug: Levocabastine nasal
Normalized name: levocabastine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine nasal spray and eyedrops
Study: 23438341
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride (700 mg)
Study: 25280410
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (control)
Study: 9305486
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for an additional 4 weeks (total 8 weeks)
Study: 8370191
Drug: Amlodipine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine combined with beta blockers and/or long-acting nitrates
Study: 3554490
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg propranolol intravenously twice daily
Study: 30317269
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment
Study: 23436315
Drug: Liquid acetaminophen
Normalized name: Acetaminophen 160 MG/5 ML Oral Solution [LIQUID ACETAMINOPHEN]
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid acetaminophen preparation (15 mg/kg)
Study: 23436315
Drug: Solid acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid acetaminophen preparation (15 mg/kg)
Study: 16626578
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg subcutaneously, Q12 h, at least twice before CAG)
Study: 16626578
Drug: UFH (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (25 mg iv before CAG with additional 65 mg iv if PCI indicated)
Study: 28656605
Drug: Somapacitan (0.02,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (0.02, 0.04, 0.08 and 0.16 mg/kg)
Study: 28656605
Drug: Norditropin® SimpleXx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norditropin® SimpleXx® (0.03 mg/kg)
Study: 18711222
Drug: GFR 45-59
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR 45-59 ml/min/1.73 m² BSA
Study: 18711222
Drug: GFR <45
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR <45 ml/min/1.73 m² BSA
Study: 16428496
Drug: MOPPEBVCAD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPPEBVCAD chemotherapy
Study: 9894256
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Radiotherapy and endocrine therapy)
Study: 29972712
Drug: Topical solution
Normalized name: Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution of 0.25% finasteride admixed with 3% minoxidil
Study: 3549804
Drug: 3% minoxidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% minoxidil solution
Study: 26585431
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral prednisolone
Study: 26585431
Drug: Medium-dose oral
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose oral prednisolone
Study: 22452604
Drug: Probiotic multistrain
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic multistrain treatment for 10 days
Study: 22452604
Drug: Probiotic multistrain
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic multistrain treatment
Study: 28159512
Drug: Sildenafil therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil therapy
Study: 16040714
Drug: Intracoronary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary vitamin C with L-NMMA and dobutamine
Study: 31072967
Drug: Oxytocin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (10 IU) administered intravenously within 15 seconds of birth
Study: 31072967
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oxytocin administered after clamping the umbilical cord 3 min after delivery)
Study: 9250235
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) with spacer devices
Study: 31375874
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder fortified with vitamin D 400 IU plus calcium 600 mg (Ca6D)
Study: 31375874
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder fortified with vitamin D 400 IU plus calcium 300 mg (Ca3D)
Study: 31375874
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder fortified with vitamin D 400 IU plus calcium 900 mg (Ca9D)
Study: 29045514
Drug: ALK inhibitor
Normalized name: an orally bioavailable ALK inhibitor (a macrocyclic compound containing nitrogen heterocycles)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALK inhibitor (ALKi)
Study: 16960937
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment for 28 weeks
Study: 10934782
Drug: Ceftazidim (CTZ)
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidim (CTZ) 1 g i.v.
Study: 10934782
Drug: Ciprofloxacin (CPF)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CPF) 400 mg i.v.
Study: 10934782
Drug: Clindamycin (CLIN)
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin (CLIN) 900 mg i.v.
Study: 29150857
Drug: 370 μg
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 370 μg LPP
Study: 29150857
Drug: 70 μg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 μg LPP
Study: 25927221
Drug: Stepwise tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stepwise tapering of remifentanil from 0.3 to 0.1 μg/kg/min for at least 30 minutes (Group B)
Study: 25927221
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil infused at 0.3 μg/kg/min until the end of surgery (Group A)
Study: 21320737
Drug: Glucomannan (GNN)
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (GNN) 2.52 g/d for 4 weeks
Study: 17420403
Drug: Retigabine 600
Normalized name: retigabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retigabine 600 mg/day
Study: 17420403
Drug: Retigabine 900
Normalized name: retigabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retigabine 900 mg/day
Study: 17420403
Drug: Retigabine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retigabine 1,200 mg/day
Study: 15482042
Drug: Abstinence reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence reinforcement with take-home methadone doses for opiate- and cocaine-free urine samples
Study: 15482042
Drug: Abstinence reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence reinforcement with take-home methadone doses and 5,800 US dollars in vouchers for cocaine-free urine samples
Study: 18069598
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors
Study: 14584860
Drug: rhPDGF-BB (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPDGF-BB (0.5 mg/ml, 1.0 mg/ml, or 5.0 mg/ml) with demineralized freeze-dried bone allograft (DFDBA)
Study: 2893417
Drug: Drug-free control
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free control group
Study: 26655398
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day RS2 for 8 weeks
Study: 3341391
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg per day)
Study: 29104158
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet with paricalcitol (2 μg per day)
Study: 29104158
Drug: High-sodium diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium diet with paricalcitol (2 μg per day)
Study: 17503984
Drug: Venlafaxine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (up to 300 mg/day)
Study: 22047719
Drug: Treatment sustainers
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment sustainers (TS)
Study: 20498120
Drug: darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir (800/100 mg)
Study: 20498120
Drug: lopinavir/ritonavir (800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (800/200 mg)
Study: 12600908
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg initially followed by 75 mg/d)
Study: 8901791
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine intake of 45.0 mg.kg‐1.d‐1
Study: 1552354
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 0.8 g.kg‐1.d‐1
Study: 1552354
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 1.0 g.kg‐1.d‐1
Study: 1807123
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotic regime
Study: 26362167
Drug: Personalized daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized daily text messaging intervention
Study: 19578224
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy (twice weekly)
Study: 19578224
Drug: Daily chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chemotherapy
Study: 11823073
Drug: Double-bolus eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-bolus eptifibatide 180/90 (30 min apart) and 1.33 microg/kg per min infusion with 50 mg t-PA (Group I)
Study: 11823073
Drug: Double-bolus eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-bolus eptifibatide 180/90 (10 min apart) and 2.0 microg/kg per min infusion with 50 mg t-PA (Group II)
Study: 7486271
Drug: Nicardipine 0.016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 0.016 mg.kg‐1
Study: 7486271
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg.kg‐1
Study: 2298002
Drug: High intravenous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intravenous glucose infusion
Study: 2298002
Drug: Low intravenous
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intravenous glucose infusion
Study: 25943183
Drug: Group P2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P2: intravenous flurbiprofen before surgery and epidural fentanyl + ketamine after surgery
Study: 7635032
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs
Study: 7840398
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-blockers and calcium channel blockers
Study: 29337835
Drug: Promethazine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (0.3 mg/kg)